News coverage about Invitae (NYSE:NVTA) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Invitae earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 45.7656262955211 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
Several research analysts recently commented on NVTA shares. Zacks Investment Research lowered shares of Invitae from a “hold” rating to a “sell” rating in a report on Thursday, January 4th. Ladenburg Thalmann Financial Services started coverage on shares of Invitae in a report on Friday, January 5th. They issued a “buy” rating and a $15.00 price target on the stock. Leerink Swann cut their price target on shares of Invitae from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, January 16th. Benchmark cut their price target on shares of Invitae from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 16th. Finally, ValuEngine lowered shares of Invitae from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Three analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Invitae currently has a consensus rating of “Hold” and an average price target of $11.00.
NYSE:NVTA traded down $0.24 during trading hours on Friday, hitting $4.98. The stock had a trading volume of 1,796,612 shares, compared to its average volume of 1,182,512. The company has a quick ratio of 2.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.35. Invitae has a 1-year low of $4.35 and a 1-year high of $10.41. The company has a market capitalization of $276.38, a price-to-earnings ratio of -1.88 and a beta of 1.06.
Invitae (NYSE:NVTA) last issued its quarterly earnings data on Monday, February 12th. The medical research company reported ($0.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.17). Invitae had a negative net margin of 180.85% and a negative return on equity of 124.43%. The firm had revenue of $25.40 million during the quarter, compared to analyst estimates of $24.18 million. During the same period last year, the business earned ($0.69) EPS. The firm’s revenue was up 175.0% compared to the same quarter last year. equities analysts anticipate that Invitae will post -2.23 earnings per share for the current year.
In other news, major shareholder Bros. Advisors Lp Baker acquired 1,111,111 shares of the stock in a transaction on Wednesday, March 28th. The stock was bought at an average price of $4.50 per share, with a total value of $4,999,999.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Randal W. Scott purchased 44,444 shares of the firm’s stock in a transaction dated Monday, April 2nd. The shares were bought at an average cost of $4.50 per share, with a total value of $199,998.00. The disclosure for this purchase can be found here. 9.90% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/invitae-nvta-receiving-somewhat-positive-press-coverage-report-shows.html.
Invitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.